Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2047-2052

  Foote, M C ^a,e   McGrath, M ^a   Guminski, A ^b   Hughes, B G M ^c   Meakin, J ^a   Thomson, D ^a   Zarate, D ^d   Simpson, F ^e   Porceddu, S V ^a,e  

^a ALEXANDRA HOSPITAL   (United Kingdom)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d QUEENSLAND HEALTH   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

cutaneous; panitumumab; squamous cell carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; PANITUMUMAB;

ADVERSE DRUG REACTION; AGED; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SKIN NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84930804244     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu368     Document Type: Article

References (22)

1. Ramirez, C.C., Federman, D.G., Kirsner, R.S., Skin cancer as an occupational disease: the effect of ultraviolet and other forms of radiation. Int J Dermatol 44 (2005), 95–100.
2. de Vries, E., van de Poll-Franse, L.V., Louwman, W.J., et al. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 152 (2005), 481–488.
3. Staples, M.P., Elwood, M., Burton, R.C., et al. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 184 (2006), 6–10.
4. Silverberg, E., Boring, C.C., Squires, T.S., Cancer statistics, 1990. CA Cancer J Clin 40 (1990), 9–26.
5. Sadek, H., Azli, N., Wendling, J.L., et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66 (1990), 1692–1696.
6. Guthrie, T.H. Jr, Porubsky, E.S., Luxenberg, M.N., et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 8 (1990), 342–346.
7. Cartei, G., Cartei, F., Interlandi, G., et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23 (2000), 181–184.
8. Shin, D.M., Glisson, B.S., Khuri, F.R., et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 20 (2002), 364–370.
9. Lippman, S.M., Kavanagh, J.J., Paredes-Espinoza, M., et al. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84 (1992), 241–245.
10. Brewster, A.M., Lee, J.J., Clayman, G.L., et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 25 (2007), 1974–1978.
11. Salomon, D.S., Brandt, R., Ciardiello, F., Normanno, N., Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995), 183–232.
12. Maubec, E., Duvillard, P., Velasco, V., et al. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 25 (2005), 1205–1210.
13. Grandis, J.R., Zeng, Q., Drenning, S.D., Tweardy, D.J., Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line. Int J Oncol 13 (1998), 375–378.
14. Camp, E.R., Summy, J., Bauer, T.W., et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11 (2005), 397–405.
15. Burtness, B., Goldwasser, M.A., Flood, W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005), 8646–8654.
16. Hecht, J.R., Mitchell, E., Neubauer, M.A., et al. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 16 (2010), 2205–2213.
17. Lewis, C.M., Glisson, B.S., Feng, L., et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18 (2012), 1435–1446.
18. Maubec, E., Petrow, P., Scheer-Senyarich, I., et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29 (2011), 3419–3426.
19. Yang, X.D., Jia, X.C., Corvalan, J.R., et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59 (1999), 1236–1243.
20. Pryor, D.I., Porceddu, S.V., Burmeister, B.H., et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90 (2009), 172–176.
21. Vermorken, J.B., Mesia, R., Rivera, F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008), 1116–1127.
22. Bonner, J.A., Harari, P.M., Giralt, J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006), 567–578.